All articles tagged with #ambroxol
A phase 2 clinical trial suggests that Ambroxol, a common cough syrup, may help stabilize psychiatric symptoms and slow cognitive decline in Parkinson’s disease dementia patients by enhancing enzyme activity that clears harmful proteins in the brain. While promising, larger studies are needed to confirm these findings and determine optimal dosing.
A phase 2 clinical trial suggests that ambroxol, an ingredient in cough medicines, may help stabilize neuropsychiatric symptoms and protect brain function in Parkinson's disease dementia, especially in genetically high-risk individuals, with further research needed to confirm its efficacy.
A clinical trial suggests that the cough medicine Ambroxol may help stabilize neuropsychiatric symptoms in Parkinson's disease dementia, especially in individuals with GBA1 gene variants, though more research is needed to confirm its efficacy and potential as a disease-modifying treatment.
Recent research suggests that ambroxol, a common cough syrup ingredient, may help slow the progression of Parkinson's disease by increasing brain waste clearance proteins and reducing alpha-synuclein accumulation, with ongoing larger trials to confirm its efficacy.
Researchers at Lawson Research Institute found that Ambroxol, a cough medicine, may slow cognitive decline and protect the brain in Parkinson's disease dementia patients, showing promise as a potential treatment, though it is not yet approved in North America.
A 12-month clinical trial suggests that Ambroxol, a cough medicine, may help slow cognitive decline and protect brain function in people with Parkinson’s disease dementia, especially in those with GBA1 gene variants, by stabilizing psychiatric symptoms and reducing brain damage markers. Although safe and well-tolerated, further research is needed to confirm its efficacy in improving cognition.